» Articles » PMID: 39038862

Childhood Neurodivergent Traits, Inflammation and Chronic Disabling Fatigue in Adolescence: a Longitudinal Case-control Study

Overview
Journal BMJ Open
Specialty General Medicine
Date 2024 Jul 22
PMID 39038862
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To test whether inflammatory processes link the expression of childhood neurodivergent traits to chronic disabling fatigue in adolescence.

Design: Longitudinal case-control study.

Setting: We analysed data from The Avon Longitudinal Study of Parents and Children (ALSPAC).

Participants: 8115 and 8036 children of the ALSPAC cohort at ages 7 and 9 years, respectively, 4563 of whom also completed self-report measures at age 18 years.

Primary And Secondary Outcome Measures: We assessed if children scoring above screening threshold for autism/attention deficit hyperactivity disorder (ADHD) at ages 7 and 9 years had increased risk of chronic disabling fatigue at age 18 years, computing ORs and CIs for effects using binary logistic regression. Mediation analyses were conducted to test if an inflammatory marker (interleukin 6 (IL-6)) at age 9 years linked neurodivergent traits to chronic disabling fatigue at age 18 years.

Results: Children with neurodivergent traits at ages 7 and 9 years were two times as likely to experience chronic disabling fatigue at age 18 years (likely ADHD OR=2.18 (95% CI=1.33 to 3.56); p=0.002; likely autism OR=1.78 (95% CI=1.17 to 2.72); p=0.004). Levels of IL-6 at age 9 were associated with chronic disabling fatigue at age 18 (OR=1.54 (95% CI=1.13 to 2.11); p=0.006). Inflammation at age 9 years mediated effects of neurodivergent traits on chronic disabling fatigue (indirect effect via IL-6: ADHD b=1.08 (95% CI=1.01 to 1.15); autism b=1.06; (95% CI=1.03 to 1.10)). All effects remained significant when controlling for the presence of depressive symptoms.

Conclusions: Our results indicate higher risk of chronic disabling fatigue for children with neurodivergent traits, likely linked to higher levels of inflammation. The implementation of transdiagnostic screening criteria to inform support strategies to counteract risk early in life is recommended.

References
1.
Fletcher-Watson S . Transdiagnostic research and the neurodiversity paradigm: commentary on the transdiagnostic revolution in neurodevelopmental disorders by Astle et al. J Child Psychol Psychiatry. 2022; 63(4):418-420. PMC: 9303713. DOI: 10.1111/jcpp.13589. View

2.
Buie T, Campbell D, Fuchs 3rd G, Furuta G, Levy J, Vandewater J . Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics. 2010; 125 Suppl 1:S1-18. DOI: 10.1542/peds.2009-1878C. View

3.
Bileviciute-Ljungar I, Maroti D, Bejerot S . Patients with chronic fatigue syndrome do not score higher on the autism-spectrum quotient than healthy controls: Comparison with autism spectrum disorder. Scand J Psychol. 2018; 59(4):428-432. DOI: 10.1111/sjop.12451. View

4.
Potts B, Smith N, Malamateniou C . Respectful language in autism research: In response to Abdelrahman et al. 'Exploration of radiographers' knowledge, attitudes, and practices in delivering healthcare to children with autism spectrum disorder.'. Radiography (Lond). 2024; 30(2):702-703. DOI: 10.1016/j.radi.2024.02.003. View

5.
Goodman R . Psychometric properties of the strengths and difficulties questionnaire. J Am Acad Child Adolesc Psychiatry. 2001; 40(11):1337-45. DOI: 10.1097/00004583-200111000-00015. View